2022: A year in Review
2022 was a year full of innovation, resilience, and creativity
Gendius was formed with a mission to help people understand and manage their diabetes better. As the company has evolved, so has our focus. In 2020, we expanded our journey of looking at how data can be used to improve patient lives by bringing in data science expertise.
Whilst we had established collaborations with academic partners at the University of Nottingham and the University of Manchester, we realised that to meet our full potential, we needed to have our own internal team of data experts. Pairing good-quality data with expertise was our obvious next step in changing the landscape of diabetes care.
Consequently, we have been expanding and developing our comprehensive, rich metabolic data set throughout the year; we now have over 100 UK primary care practices that share pseudonymised patient data to support our vision. Alongside this, our data science team was born. With two postdoctoral health data scientists, we have managed to hit the ground running on our data science pathway, leading us to our most exciting innovation of the year: the CKD Screening Prioritizer.
The CKD Screening Prioritizer was developed by our data science team, published in a peer-reviewed journal, validated across global datasets and presented at international expert conferences. Its overwhelming performance compelled us to build a platform that can be used across global healthcare services. We are now in the implementation phase, where clinics and patients will be provided access to the tool, supported by AstraZeneca.
Building this has given us a clear insight into the land of opportunity in supporting the care of people with chronic diseases. It has demonstrated how our team are well suited to develop solutions in this space, indicated where we can help patients the most and motivated our 2023 priority projects. The work we are doing is ultimately about saving lives and reducing the ever-growing cost burden that healthcare systems face, globally.
Reflecting our Values & Vision
The creative team at Gendius evolved our core brand identity at the start of 2022 to create alignment with the company direction and culture. In total Gendius is made up of 15 talented individuals, this design project involved and united the whole team, the outcome created momentum and motivation for 2022’s workstream.
Inclusivity and accessibility are a core part of our work at Gendius and were embedded throughout the brand update. You can read more about the specifics of the design here – Gendius brand upgrade
Our new Gendius website was launched this year to provide a space for us to showcase our products, team members and exciting updates.
The CKD Screening Prioritizer (CSP)
Our state-of-the-art CKD Screening Prioritizer (CSP) will enable healthcare professionals to identify patients with type 2 diabetes that are likely to be experiencing abnormal kidney function. Predicting an individual’s risk of developing chronic kidney disease (CKD) means they can be prioritized for the life-extending treatment they require sooner.
The data science, design and development teams created the product with flexible implementation methods for different healthcare system needs.
Our lead data scientist commented on the project:
“Our pragmatic and creative approaches have led us to something that I believe could be a game-changer for patients and healthcare systems, and I cannot wait to showcase its real-world impact.”
Dr Camilla Sammut-Powell
Team Growth in 2022
In 2022 we hired four additional team members to support the delivery of our world class projects.
Ali Borazjani joins the team as Head of Quality Assurance and Regulatory Affairs. His background is in Medical Engineering, At Gendius he is using his expertise to implement a fully compliant QMS and obtain regulatory clearance to market the CSP and intellin Platform globally. With his support, we passed the ISO 27001 surveillance audit this year and have Stage one scheduled for February 2023.
Claudia Federico combines creativity, empathy and analytical skill to optimise user experiences. She is passionate about inclusive design, an advocate for digital accessibility and has extensive knowledge of Design Systems, design regulations and agile processes. As Lead Product Designer, Claudia has transformed the Gendius brand and communications. She has worked with our data scientists and developers to create the CSP product brand and user interface. She is also working across all our other product projects and providing investor communication content.
Hannah Lacey is a full stack developer with a background in visual art, passionate about problem solving, creativity and community. Experienced in web and mobile development and focused on producing clean, high quality code and design, she has already proved an asset to the development team working on all projects across both the intellin and Gendius brands.
Emily McBride is a marketing professional with a background in Media Psychology. Interested in diversity, inclusion and communication, she has taken over as the Social Media and Content Marketing Executive. In her time with us, Gendius has grown its overall audience on social media by over 56% and seen an increase in engagement of over 15%.
Our Contributions to the Scientific Community
We are dedicated to creating movement and innovation in patient care, sharing our work with the scientific and healthcare communities is our way of ensuring we are maximising our impact.
This year Gendius has published a study in the Future Healthcare Journal (FHJ) which details our development of the minimal resource pre-screening tool for chronic kidney disease in people with type 2 diabetes.
We published our conference abstracts for the European Association for the Study of Diabetes (EASD) annual meeting in September and the American Society of Nephrology (ASN) Kidney week in November. At both EASD and ASN, our data science team gave presentations going into the details on the global validation of our model.
In the later part of 2022 we published a feasibility study based on our work within the intellin platform. This publication focused specifically on the patient population with diabetic foot ulceration and highlights the benefits of active self-monitoring and pro-active care.
Link to the full study publication
